3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, announced the appointment of Rebeca Villarreal-Barragan, MBA, as head of clinical operations. In this role, Ms....
first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon's lead candidate, NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS). HEALEY ALS Platform Trial The HEALEY ALS Platform Trial...
from Ben Gurion University and an MBA from Tel Aviv University. He has served as CEO and owner of RonMed Ltd. since 2015 and brings decades of executive leadership experience in the healthcare and life sciences sectors. Over the past 5 years, Mr....
Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables more...
review, applied artificial intelligence and bioinformatics solutions, and more. About ARUP Laboratories: Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah Spencer Fox...
repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with...
Bruker Corporation announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional...
67Cu-SAR-bisPSMA (8 GBq each cycle). The participant is a 76-year-old man who was initially diagnosed with prostate cancer 15 years ago. He had radical prostatectomy to treat the primary disease and radiotherapy for local recurrence, having...
U.S. Food and Drug Administration (FDA) and European Commission have granted Orphan Drug Designation to deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF), a rare, progressive, and fatal lung disease. Deupirfenidone...
MSD outside of the United States and Canada, announced positive second RSV season findings from the Phase 3 SMART trial (MK-1654-007) (NCT04938830) evaluating the safety, efficacy and pharmacokinetics of ENFLONSIA™ (clesrovimab) in infants and...
completed treatment without interruption. At three months post-treatment, local control within the re-irradiated volume was 100%, with complete metabolic response, partial response, or stable disease observed in all evaluable patients. Acute...
Precision AQ, a global commercialisation partner built to guide life science innovators through commercial complexity, announced the appointment of two new leaders who will accelerate the company's international growth and enhance delivery of...
Crohn’s disease (CD) and ulcerative colitis (UC) patients with sustained efficacy, safety, and persistence through to Week 102. The data will be presented as a poster presentation at the 21st Congress of the European Crohn’s and Colitis...
IRBM, a leader in early drug discovery research, has announced a major scientific breakthrough with the discovery of a novel and potent allosteric inhibitor targeting the Zika virus (ZIKV) protease (NS2B-NS3). The findings, published in Nature...
levels (as low as 40 ppm) suppressed genes associated with proliferation and drug resistance (e.g., MYCN, ETS2, ABCB1), while high deuterium environments (300 ppm) upregulated multiple oncogenic and survival pathways (EGFR, CTNNB1, STAT3, CD44)....
affects communication between nerves and muscles.¹ RYSTIGGO® is administered as a weekly infusion of 3mL-6mL of drug over 15-30 minutes for 6 weeks, with subsequent treatment cycles based on clinical evaluation.¹ “With this new FDA clearance, we...
Corp. a fully integrated, commercial biotechnology company, presented data on TONMYA™, which was investigated as TNX-102 SL, at the 2026 Non-Opioid Pain Therapeutics Summit, on January 29, 2026, in Boston, Massachusetts. A copy of the Company's...
virus infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of the large envelope protein of hepatitis B virus (HBV) and hepatitis D virus (HDV), thereby blocking viral entry...
lenalidomide and dexamethasone (VRd) in NDMM patients who were ineligible for ASCT or deferred ASCT as initial therapy.1 Today's milestone follows approval for D-VRd for the treatment of patients who are newly diagnosed with multiple myeloma and...
Privo Technologies, Inc. announced the successful completion of its Phase 1/2 clinical evaluation of PRV211, a first-in-class intraoperative chemotherapy patch for head and neck cancer patients. The study demonstrated excellent safety outcomes...
